Alice Scott Mims MD MSCR

Hematologic Oncology

Professor, Medicine, The Ohio State University/James Cancer Hospital and Solove Research Institute

460 W 10th AveJames 5th FloorColumbus, OH 43210
Phone+1 614-293-5655
Fax+1 614-293-7526

Dr. Mims is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mims' full profile Already have an account?

Summary

Acute leukemias and myeloid malignancies

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2011
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2005 - 2008
Medical University of South CarolinaClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2009 - 2028
SC State Medical License 2012 - 2017
NC State Medical License 2005 - 2012
IA State Medical License 2008 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2015
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2015
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015

Clinical Trials

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
TERMINATED
PHASE3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
COMPLETED
PHASE2

Publications & Presentations

PubMed

CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study.
Shivani Handa, Yazan Madanat, Kelly Pugh, Kaitlyn Dvorak-Kornaus, Qiuhong Zhao
Blood Neoplasia. 2026-11-01
Randomized phase II trial of liposomal cytarabine and daunorubicin with or without pomalidomide in newly diagnosed acute myeloid leukemia myelodysplasia-related.
Daniel T Peters, Kristin Koenig, Anastasia Ivanova, Jiajun He, Gail J Roboz
Haematologica. 2026-09-24
2 citations
RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.
Bettina Nadorp, Audrey Lasry, Sanam Loghavi, Ravi Patel, Hager Mansour
Blood Cancer Discovery. 2026-09-03

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome
Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

New Agents in Myeloid Malignancies
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Multi-Institutional Team Awarded NCI Grant to Open Novel AML TrialJune 23rd, 2025
Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
Add-on Venetoclax Promising in Younger, Fit AML PatientsJuly 30th, 2021

Grant Support

Dual Targeting of Oncogenic Signaling and Immune Suppression in High-Risk T-ALLOHIO STATE UNIVERSITY2026–2031
Pharmacodynamically directed targeted therapy for leukemiaUNIVERSITY OF PITTSBURGH AT PITTSBURGH2025–2030
Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AMLOHIO STATE UNIVERSITY2022–2028
Targeting NAMPT in Acute Myeloid LeukemiaOHIO STATE UNIVERSITY2018–2025